REVENUE (Tables)

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table summarizes the disaggregation of revenue by nature:

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in millions	2023		2022		2023		2022
Net product sales	$	10,645	$	10,813	$	32,610	$	33,606
Alliance revenues	138		173		461		560
Other revenues	183		232		458		587
Total Revenues	$	10,966	$	11,218	$	33,529	$	34,753

Revenue Recognition Gross-To-Net Adjustments

The following table summarizes GTN adjustments:

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in millions	2023		2022		2023		2022
Gross product sales	$	18,648	$	17,606	$	54,047	$	51,555
GTN adjustments (a)
Charge-backs and cash discounts	(2,373)		(1,907)		(6,743)		(5,420)
Medicaid and Medicare rebates	(3,730)		(3,295)		(9,355)		(8,003)
Other rebates, returns, discounts and adjustments	(1,900)		(1,591)		(5,339)		(4,526)
Total GTN adjustments	(8,003)		(6,793)		(21,437)		(17,949)
Net product sales	$	10,645	$	10,813	$	32,610	$	33,606

(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $18 million and $116 million for the three and nine months ended September 30, 2023 and $10 million and $207 million for the three and nine months ended September 30, 2022, respectively.

Revenue from External Customers by Products and Services

The following table summarizes the disaggregation of revenue by product and region:

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in millions	2023		2022		2023		2022
In-Line Products
Eliquis	$	2,705	$	2,655	9,332		9,101
Opdivo	2,275		2,047		6,622		6,033
Pomalyst/Imnovid	872		886		2,551		2,620
Orencia	925		883		2,616		2,551
Sprycel	517		560		1,404		1,587
Yervoy	579		523		1,672		1,563
Mature and other products	476		514		1,415		1,563
Total In-Line Products	8,349		8,068		25,612		25,018
New Product Portfolio
Reblozyl	248		190		688		518
Abecma	93		107		372		263
Opdualag	166		84		437		148
Zeposia	123		69		301		171
Breyanzi	92		44		263		127
Onureg	43		32		121		87
Inrebic	29		21		81		62
Camzyos	68		5		143		8
Sotyktu	66		1		107		1
Total New Product Portfolio	928		553		2,513		1,385
Total In-Line Products and New Product Portfolio	9,277		8,621		28,125		26,403
Recent LOE Products(a)
Revlimid	1,429		2,420		4,647		7,718
Abraxane	260		177		757		632
Total Recent LOE Products	1,689		2,597		5,404		8,350
Total revenues	$	10,966	$	11,218	$	33,529	$	34,753
United States	$	7,628	$	7,941	$	23,552	$	23,903
International	3,153		3,062		9,462		10,216
Other(b)	185		215		515		634
Total revenues	$	10,966	$	11,218	$	33,529	$	34,753

(a)    Recent LOE Products include products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity.

(b)    Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations.